Sintilimab Combined With Bevacizumab as Neoadjuvant Therapy for Resectable Hepatocellular Carcinoma Beyond the Milan Criteria: A Single-Arm, Prospective Phase II Study
概览
- 阶段
- 2 期
- 状态
- 招募中
- 发起方
- Sun Yat-sen University
- 入组人数
- 37
- 试验地点
- 1
- 主要终点
- 1-year recurrence free survival rate
概览
简要总结
Surgical resection is the preferred therapeutic modality for patients with resectable hepatocellular carcinoma (HCC). However, the recurrence rate of HCC remains up to 70%. Neoadjuvant therapy for HCC could potentially reduce the risk of postoperative recurrence and prolong overall survival. Nevertheless, there is no standard neoadjuvant treatment regimen for HCC to date. In recent years, targeted therapy and immunotherapy are proved to improve the prognosis of advanced HCC patients. Previous study (ORIENT-32) has confirmed that, compared with sorafenib, sintilimab combined with bevacizumab biosimilar can delay tumor progression, reduce the risk of death, and exhibit a favorable safety profile in patients with advanced HCC. Therefore, we conducted a prospective, single-arm phase II study to investigate the efficacy of sintilimab combined with a bevacizumab biosimilar as neoadjuvant therapy in patients with resectable HCC beyond the Milan criteria.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Able to provide informed consent and willing to sign an approved consent form;
- •Aged ≥ 18 years;
- •Clinically diagnosed or pathologically confirmed resectable hepatocellular carcinoma beyond the Milan criteria (CNLC Ib-IIa);
- •No prior anti-HCC treatment;
- •Child-Pugh class A.
- •Eastern Cooperative Oncology Group (ECOG) performance status score of 0-
- •Expected survival time of \> 6 months.
- •Sufficient organ and bone marrow function.
排除标准
- •Known as cholangiocarcinoma (ICC) or mixed hepatocellular carcinoma, sarcomatoid hepatocellular carcinoma, and hepatic fibrolamellar carcinoma;
- •History of organ transplantation or hepatic encephalopathy
- •Pleural fluid, ascites, and pericardial effusion with clinical symptoms requiring drainage
- •History of esophageal or gastric variceal bleeding caused by portal hypertension within the past 6 months; Documented severe (Grade 3) varices identified by endoscopy within 3 months prior to enrollment; Evidence of portal hypertension and assessed by the investigator as being at high risk of bleeding.
- •Arterial and venous thromboembolic events in the past 6 months, including myocardial infarction, unstable angina, cerebrovascular accident or transient ischemic attack, pulmonary embolism, deep vein thrombosis or any other serious thromboembolism history;
- •Any life-threatening bleeding event occurring within the past 3 months;
- •Severe bleeding tendency, coagulopathy, or ongoing thrombolytic therapy.
- •Chronic requirement for medications that inhibit platelet function, such as aspirin (\>325 mg/day), dipyridamole, or clopidogrel.
- •Uncontrolled hypertension, defined as systolic blood pressure \>140 mmHg or diastolic blood pressure \>90 mmHg despite optimal medical management; history of hypertensive crisis or hypertensive encephalopathy.
- •Symptomatic congestive heart failure (New York Heart Association \[NYHA\] Functional Class II-IV); symptomatic or poorly controlled arrhythmias; history of congenital long QT syndrome; or corrected QT interval (QTc) \>500 ms at screening (calculated using Fridericia's formula).
研究组 & 干预措施
sintilimab combined with bevacizumab biosimilar
干预措施: sintilimab combined with bevacizumab biosimilar (Drug)
结局指标
主要结局
1-year recurrence free survival rate
时间窗: Up to 2 years
Defined as the proportion of patients who remain free from any tumor recurrence or death within 1 year after liver resection.
Adverse Events (AEs)
时间窗: Up to 2 years
Defined as the proportion of patients with AEs assessed by NCI CTCAE v5.0;
次要结局
- Time to recurrence(Up to 2 years)
- R0 resection rate(Up to 2 years)
- pathological complete response(Up to 2 years)
- major pathological response(Up to 2 years)
- Overall survival(Up to 2 years)
- Recurrence free survival(Up to 2 years)
研究者
Zhongguo Zhou
Principal Investigator
Sun Yat-sen University